Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc6.5 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma

Gesmundo Iacopo , Vitale Nicoletta , Orlando Giulia , Bertoldo Alessia , Papotti Mauro , Deaglio Silvia , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due exposure to asbestos. Of note, different growth factors and their receptors are involved in the pathogenesis of MPM and resistance to therapy. Chemotherapy with cisplatin (cis) and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), besides stimulating GH secretion in the ant...